ALBA MANUEL

Director Manuel sold 183,000 shares (183.0K shares) for $19,693,396.64 across 7 transactions on 2026-04-01, reducing stake by 36.4%

Director Alba Manuel executed 7 separate sales totaling 183,000 shares for $19,693,396.64 at prices ranging from $106.32 to $111.14, reducing her holdings from 502,863 shares to 319,863 shares—a 36.4% reduction in her position. The transaction occurred at a blended average price of $107.61, notably below the current market price of $117.14, suggesting the sales preceded a subsequent price advance. Within the same ticker (ALAB), Manuel's 5 prior sales—all conducted on 2025-12-01—showed a 100% well-timed pattern at the 90-day mark, with returns ranging from -26.0% to -31.1%, indicating those sales preceded declines. Her cross-ticker track record shows 20 prior sells with an average 90-day return of -27.0% and a 90-day well-timed rate of 100.00%, demonstrating consistent downside capture before market reversals. This transaction's scale (36.4% of prior holdings), coupled with the insider's established pattern of well-timed exits and current price positioning $9.53 above the blended sale price, warrants close monitoring of whether this divestiture signals a shift in insider positioning at a company with strong fundamentals (annual revenue growth of +115.1%, P/E of 39.71).

ALAB director Manuel sold 150,000 shares for $24.9M in 19 separate sales on 2025-12-01; stock down 39.5% from 52-week high, post-trade holds 1.57M shares.

Manuel executed 19 separate sales totaling 150,000 shares (150.0K shares) for $24,927,221.35 ($24.9M) on a single day, reducing holdings from 1.72M shares to 1.57M shares. The blended average sale price of $166.18 contrasts sharply with the current price of $152.50 and reflects a stock down 39.5% from its 52-week high of $251.88. Across his cross-ticker open-market history, Manuel's prior sells showed a 100.00% well-timed rate with an average 90-day return of -3.5%, suggesting historical acumen in identifying sell windows; however, this is his first sale at ALAB with measurable outcomes pending. The company reports strong fundamentals with $230.6M quarterly revenue and +242.2% annual revenue growth, yet trades at a P/E of 129.24 and was unprofitable on a full-year basis, indicating significant valuation tension. The sale's scale and timing warrant monitoring as the 30-day price movement already shows -20.4% since the transaction.

Director Alba Manuel sells 33,000 ALAB shares for $5.5M on 2025-12-01 as stock declines 20.4% in 30 days.

Alba Manuel (Director) executed 19 separate sales totaling 33,000 shares for $5,483,980.58, representing an 8.6% reduction in holdings post-transaction. The sales occurred across a range of prices from $153.80 to $171.57, with a blended average of $166.18, while the current market price of $152.50 reflects a 39.5% decline from the 52-week high and a 20.4% drop over the past 30 days. Manuel's cross-ticker track record shows 20 prior sells with a 100% well-timed rate at the 90-day mark, suggesting a pattern of selling before declines; however, these prior results come from multiple tickers and cannot be directly extrapolated to ALAB performance. The timing of this large block sale coincides with significant near-term price deterioration, and with ALAB trading at a 129.24 P/E ratio against full-year net losses, the transaction occurs during a period of elevated volatility and valuation stress.

Director Alba Manuel sells 183,000 shares (32.2% of holdings) for $31.7M at blended avg $173.27 on 2025-09-02

Director Alba Manuel executed 26 separate sales on 2025-09-02 totaling 183,000 shares for $31,707,713.22, reducing holdings from 568,863 to 385,863 shares. The sales spanned a 7-transaction price range from $168.23 to $180.10, with a blended average price of $173.27, 2.9% below the current price of $187.95. Against his cross-ticker track record of 20 prior sells averaging 30-day returns of +44.6%, the five prior sells at ALAB (all in July 2025) showed consistently positive 30-day returns (41.9%–55.4%), with 90-day outcomes not yet measurable. The disposition of a full third of his stake in a single concentrated trading day, combined with the stock's substantial appreciation (+38.7% over 30 days and +107.1% over 90 days), reflects a significant reduction in this director's exposure to the company.

Director Manuel sold 13,259 shares of ALAB at $111.00 on 2025-07-21, now -18.1% from 52-week high; recent 30-day surge +39.0%.

Director Alba Manuel sold 13,259 shares (13.3K shares) of Astera Labs at $111.00 on 2025-07-21, retaining 1,874,498 shares (1.87M shares) post-transaction. The sale follows a sharp recent appreciation: the stock is up +39.0% over 30 days and +85.1% over 90 days, though it remains -18.1% from its 52-week high of $145.81. Fundamentally, the company reported revenue of $159,442,000.00 ($159.4M) in the latest quarter and net income of $31,819,000.00 ($31.8M), with annual revenue growth of +242.2%, though the company was unprofitable over its most recent full fiscal year. The sale represents a modest -0.7% reduction in holdings and occurs within a pattern of five prior sales at ALAB on 2025-07-03, outcomes of which are not yet measurable.

Director Manuel sold 93,991 shares ($8.5M) over 2 days at $88.71–$93.14, reducing stake 4.7% to 1.89M shares.

Director Alba Manuel executed 20 separate sales totaling 93,991 shares for $8,490,867.37 ($8.5M) across July 2–3, 2025, at prices ranging from $88.71 to $93.14 (blended average $90.34), reducing holdings by 4.7% to 1,887,757 shares. The stock is currently down 38.5% from its 52-week high of $145.81 and has posted strong 90-day performance (+66.9%) despite recent weakness (-1.2% over 30 days), creating a backdrop of elevated volatility. At the same ticker, Manuel's prior April 2025 sell subsequently returned +50.4% over 90 days, and his cross-ticker track record shows 0.00% well-timed sells (positive average 90d return of +48.0% means prior sells were followed by stock appreciation), neither pattern suggesting prescient downside timing. The sale's magnitude and timing—concentrated over two trading days—warrant monitoring for context on capital deployment or portfolio rebalancing, though the fundamentals remain extreme (P/E 358.48, full-year net income negative despite latest quarter profitability).

Director ALBA MANUEL sells 20,150 shares for $2.0M at $100.84 avg; stock down 40.2% from 52-week high of $145.81

ALBA MANUEL, Director at Astera Labs, executed 4 separate sales totaling 20,150 shares for $2,031,852.89 at a blended average price of $100.84. The sale represents a 1.0% reduction in holdings, leaving 1,967,757 shares post-transaction. The transaction occurred as the stock trades at $87.26, down 40.2% from its 52-week high of $145.81 and down 7.8% over the prior 30 days, suggesting the insider sold well above current levels. Across his 5 prior trades at ALAB on 2025-04-03, his subsequent 30-day returns ranged from +21.0% to +25.1%, indicating the insider's prior ALAB sales preceded periods of stock appreciation. The company carries a P/E of 349.04 and reported negative full-year net income despite recent quarterly profitability of $31.8M on $159.4M revenue and annual growth of +242.2%, reflecting high valuation against profitability uncertainty.

Director Alba Manuel sells 100,000 shares (4.8% of holdings) across 21 transactions for $6.1M; stock down 22.8% in 30 days, 62.4% in 90 days.

Alba Manuel, a director at Astera Labs, executed 21 separate sales totaling 100,000 shares for $6,093,537.00 between April 2–3, 2025, at prices ranging from $55.97 to $65.14, with a blended average of $60.94. The current stock price of $52.94 represents a -63.7% decline from the 52-week high of $145.81, and the stock has fallen -22.8% in the 30 days and -62.4% in the 90 days following these transactions. Notably, across his prior 5 trades at ALAB, all were well-timed at the 90-day mark, with each showing negative 90-day returns averaging -40.9%; this sale aligns with that pattern as the stock has already declined 62.4% post-transaction. The company reported $113.1M in latest-quarter revenue with a net loss of $7.6M, and despite +242.2% annual revenue growth, remains unprofitable on a full-year basis, which may have factored into the director's decision to reduce his stake from 2,084,498 to 1,984,498 shares.

Director Alba Manuel sold 11,000 shares at $115.53–$121.05 on 2024-12-04 for $1,292,531.46; stock at 52-week high.

Director Alba Manuel executed 7 separate sales totaling 11,000 shares for $1,292,531.46 at prices ranging from $115.53 to $121.05, with a blended average of $117.50. The sale occurred with the stock at its 52-week high of $120.40, following a 22.6% gain over the prior 30 days and a 201.0% surge over 90 days. Manuel retained 2,064,498 shares post-transaction, a 0.5% reduction in holdings. His prior trades at ALAB (5 discrete transactions on 2024-12-03) remain too recent for outcome measurement, and no historical timing pattern is yet available at this ticker. The sale's significance is underscored by its volume relative to ALAB's market cap ($19.1B) and the director's substantial retained stake, despite the company reporting a loss of $7,593,000.00 in the latest quarter.

Director Alba Manuel sells 126,000 shares ($13.6M) over Dec 2–3; retains 2.07M shares post-transaction

Alba Manuel, a director at Astera Labs, executed 29 separate sales totaling 126,000 shares for $13,593,864.79 at prices ranging from $101.60 to $116.59 across December 2–3, 2024, achieving a blended average price of $107.89. The sale reduces her stake by 5.7% but leaves substantial holdings of 2,072,498 shares (2.07M shares). The timing coincides with a sharp recent run—the stock has gained 65.5% over 30 days and 176.5% over 90 days, trading near its 52-week high of $116.51. The multi-transaction structure across two consecutive trading days and price actions spanning a $15 range suggest a systematic execution rather than panic liquidation. Investors should note that while the sale occurs in a favorable price environment, the insider retains a significant position, and the company's latest quarter showed a net loss of $7,593,000.00 despite $113,086,000.00 in revenue.